semaglutide and iih intracranial hypertension Awareness, Diagnosis Management of Idiopathic Intracranial Hypertension Visual field changes seen in

Patients without diabetes averaged a 24 percent body weight loss in just 48 weeks (11 months)

Pharmaceutical companies are investing in next-generation analogues with extended half-lives, improved bioavailability, and once-weekly or even monthly dosing regimens

suggests that care should be taken when prescribing contact lens use in these people

Individuals with restrictive eating disorders, fasting behaviors, or weight-driven purging may be at increased risk of symptom reactivation and are not appropriate candidates

In the SURMOUNT-1 trial targeting non-diabetic patients with obesity, tirzepatide achieved an impressive 22.5% reduction in body weight after 72 weeks, surpassing other drugs [55]

Dosage: Higher doses of semaglutide may increase the likelihood of aches